S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

APGE Apogee Therapeutics Inc

31.43

0.00 (0.00%)

Pre Market

Last Updated: 21:54:24

Delayed by 15 minutes

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Apogee Therapeutics (NASDAQ:APGE)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Apogee Therapeutics Charts.

Apogee Therapeutics (NASDAQ:APGE)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Apogee Therapeutics Charts.

Apogee Therapeutics Inc News

Form 8-K - Current report
Monday 3 March 2025 (3 days ago) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Monday 3 March 2025 (3 days ago) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Monday 3 March 2025 (3 days ago) • Edgar (US Regulatory)

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
Monday 3 March 2025 (3 days ago) • GlobeNewswire Inc.

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
Monday 3 March 2025 (3 days ago) • GlobeNewswire Inc.

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
Saturday 1 March 2025 (6 days ago) • GlobeNewswire Inc.

Apogee Therapeutics to Participate in Upcoming March Investor Conferences
Tuesday 25 February 2025 (1 week ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 8 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 3 February 2025 (1 month ago) • Edgar (US Regulatory)

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
Monday 3 February 2025 (1 month ago) • GlobeNewswire Inc.

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
Wednesday 29 January 2025 (1 month ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 4 January 2025 (2 months ago) • Edgar (US Regulatory)

More Apogee Therapeutics Inc News Articles

Verizon Communications

Sterling vs AUD

Newcrest Mining

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions